<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18744" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>C Reactive Protein</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nehring</surname>
            <given-names>Sara M.</given-names>
          </name>
          <aff>St Bernards Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Bhupendra C.</given-names>
          </name>
          <aff>University of Utah</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Nehring declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18744.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>C-reactive protein (CRP) was discovered by Tillett and Francis in 1930. The name CRP arose because it was first identified as a substance in the serum of patients with acute inflammation that reacted with the "c" carbohydrate antigen of the capsule of pneumococcus.</p>
        <p>CRP is a pentameric protein synthesized by the liver, whose level&#x000a0;rises in response to&#x000a0;inflammation.&#x000a0;CRP is an acute-phase reactant protein that is primarily induced by the IL-6 action on the gene responsible for the transcription of CRP during the acute phase of an inflammatory/infectious process. There is some&#x000a0;question about whether dysregulation of the role of CRP in the clearance of apoptotic cells and cellular debris plays a role in the pathogenesis of systemic lupus erythematosus (SLE), but this has not been definitively demonstrated. It has been demonstrated to have some&#x000a0;protective properties in animal studies on lung tissue in alveolitis by reducing neutrophil-mediated damage to the alveoli and protein leakage into the lung.</p>
        <p>CRP has both proinflammatory&#x000a0;and anti-inflammatory properties. It plays a role in the recognition and clearance of foreign&#x000a0;pathogens and damaged cells&#x000a0;by binding to phosphocholine, phospholipids, histone, chromatin, and fibronectin. It can activate the classic complement pathway and also activate phagocytic cells via Fc receptors to expedite the removal of cellular debris and damaged or apoptotic cells and foreign pathogens.&#x000a0;This can become pathologic, however, when it is activated by autoantibodies displaying the phosphocholine arm&#x000a0;in auto-immune processes, such as&#x000a0;idiopathic&#x000a0;thrombocytopenic purpura (ITP). It can also worsen tissue damage in certain cases by activation of the complement system and thus inflammatory cytokines.<xref ref-type="bibr" rid="article-18744.r1">[1]</xref><xref ref-type="bibr" rid="article-18744.r2">[2]</xref><xref ref-type="bibr" rid="article-18744.r3">[3]</xref></p>
        <p>As compared to the erythrocyte sedimentation rate, which is an indirect test for inflammation, the levels of CRP rise and fall rapidly with the onset and removal of the inflammatory stimulus, respectively. Persistently elevated CRP levels can be seen in chronic inflammatory conditions such as chronic infections or inflammatory arthritides such as rheumatoid arthritis.</p>
        <p>There are numerous causes of an elevated C-reactive protein.&#x000a0; These include acute and chronic conditions, and these can be infectious or non-infectious in etiology. However, markedly elevated levels of CRP are most often associated with an infectious cause<xref ref-type="bibr" rid="article-18744.r4">[4]</xref> (an example of pathogen-associated molecular pattern recognition).&#x000a0; Trauma can also cause elevations in CRP (alarmin response). More modest elevations tend to be associated with a broader spectrum of etiologies, ranging from sleep disturbances to periodontal disease.</p>
      </sec>
      <sec id="article-18744.s2" sec-type="Specimen Collection">
        <title>Specimen Collection</title>
        <p>A blood specimen is taken from&#x000a0;a peripheral venous draw. A phlebotomist performs the procedure in most cases. The&#x000a0;phlebotomist&#x000a0;secures a snug rubber band around the upper arm, and the patient pumps his or her fist several times. The&#x000a0;phlebotomist&#x000a0;palpates the vein to confirm the location and cleanses the area with an alcohol prep pad. Once the area air dries, the practitioner introduces a needle into the vein and draws a vial of blood. He or she&#x000a0;removes the band from the patient's arm and then removes the needle and applies pressure to the venipuncture site until hemostasis occurs, usually within one minute. A bandage is applied over the site.</p>
        <p>The patient's medications should be reviewed, as these can affect the outcome of the test. Fasting is not required before the blood draw. There are no special procedures required. Complications include oozing at the draw site, bruising or mild tenderness at the site, or very&#x000a0;rarely, infection at the venipuncture site.&#x000a0;Other bodily fluids, such as synovial fluid, can be tested for in this manner but frequently are not.</p>
        <p>Immunoassays and laser nephelometry are the methods to quantify CRP levels and are cheap, accurate, and fast. To detect lower levels of CRP (0.3 to 1.0 mg/L), high-sensitivity CRP methods are recommended as the usual CRP detection tests are less precise.&#x000a0;High-sensitivity CRP only denotes the assay process used, allowing for detection of lower levels of CRP and not a different, or more specific, differential diagnosis.</p>
      </sec>
      <sec id="article-18744.s3" sec-type="Indications">
        <title>Indications</title>
        <p>This test is performed when the physician suspects acute or chronic inflammation (e.g., SLE or rheumatoid arthritis [RA]) or infection. The utility of the hs-CRP for cardiac screening is debatable.&#x000a0;There is some&#x000a0;correlation between cardiovascular risk and elevated hs-CRP, but the application of this is still&#x000a0;controversial especially given the poor specificity of this test, and it is currently&#x000a0;undergoing more evaluation.<xref ref-type="bibr" rid="article-18744.r5">[5]</xref><xref ref-type="bibr" rid="article-18744.r6">[6]</xref><xref ref-type="bibr" rid="article-18744.r7">[7]</xref></p>
      </sec>
      <sec id="article-18744.s4" sec-type="Normal and Critical Findings">
        <title>Normal and Critical Findings</title>
        <p>Lab values vary, and there is no standard at present.&#x000a0; However, in general, the result is reported in either mg/dL or mg/L. Hs-CRP is usually reported in mg/dL.&#x000a0;When used for cardiac risk stratification, hs-CRP levels less than 1 mg/dL are considered&#x000a0;low risk. Levels between 1&#x000a0;mg/dL&#x000a0;and 3 mg/dL are considered a moderate risk, and a level greater than 3 mg/dL is considered&#x000a0;high risk for the development of cardiovascular disease.<xref ref-type="bibr" rid="article-18744.r8">[8]</xref><xref ref-type="bibr" rid="article-18744.r9">[9]</xref>&#x000a0;</p>
        <p>
<bold>Interpretation of CRP levels:</bold>
</p>
        <p>Less than 0.3 mg/dL: Normal (level seen in most healthy adults).</p>
        <p>0.3 to 1.0 mg/dL: Normal or minor elevation (can be seen in obesity, pregnancy, depression, diabetes, common cold, gingivitis, periodontitis, sedentary lifestyle, cigarette smoking, and genetic polymorphisms).</p>
        <p>1.0 to 10.0 mg/dL: Moderate elevation (Systemic inflammation such as RA, SLE, or other autoimmune diseases, malignancies, myocardial infarction, pancreatitis, bronchitis).</p>
        <p>More than 10.0 mg/dL: Marked elevation (Acute bacterial infections, viral infections, systemic vasculitis, major trauma).</p>
        <p>More than 50.0 mg/dL: Severe elevation (Acute bacterial infections).</p>
      </sec>
      <sec id="article-18744.s5" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Certain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), will falsely decrease CRP levels. Statins, as well,&#x000a0;have been known to reduce CRP levels falsely. Recent injury or illness can falsely elevate levels, particularly when using this test for cardiac risk stratification. Magnesium supplementation also can decrease CRP levels.</p>
        <p>As mentioned above, mild elevations in CRP can be seen without any systemic or inflammatory disease. Females and elderly patients have higher levels of CRP. Obesity, insomnia, depression, smoking, and diabetes can all contribute to mild elevations in CRP, and the results shall be interpreted with caution in individuals with these comorbidities.</p>
      </sec>
      <sec id="article-18744.s6" sec-type="Complications">
        <title>Complications</title>
        <p>Given the highly variable causality of elevated CRP, marginal elevations in the CRP can be difficult to interpret and should not be used as&#x000a0;an isolated test result interpreted as appropriate for the clinical picture. It is useful in suggesting infection versus inflammation if the levels are extremely&#x000a0;high, but levels between 1 mg/dL and 10 mg/dL can be difficult to interpret accurately. Chronic conditions, such as inflammatory arthritis or SLE, can make these levels elevated chronically, making&#x000a0;it harder to determine if there is any significance to an elevated hs-CRP level when using it as a predictive marker for cardiovascular disease.</p>
      </sec>
      <sec id="article-18744.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Very high levels of CRP, greater than 50 mg/dL, are associated with bacterial infections about 90% of the time. In multiple studies, CRP has been used as a prognostic factor in acute and chronic infections, including hepatitis C, dengue, and malaria.&#x000a0;<xref ref-type="bibr" rid="article-18744.r10">[10]</xref><xref ref-type="bibr" rid="article-18744.r11">[11]</xref><xref ref-type="bibr" rid="article-18744.r12">[12]</xref>&#x000a0;On the other hand, mild elevations may or may not be clinically relevant. Clinical correlation is strongly recommended while interpreting the results of the CRP test.</p>
      </sec>
      <sec id="article-18744.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18744&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18744">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18744/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18744">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18744.s9">
        <title>References</title>
        <ref id="article-18744.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cleland</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Eranki</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <chapter-title>Procalcitonin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">30969616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jungen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ter Meulen</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>van Osch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ostelo</surname>
                <given-names>RWJG</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory biomarkers in patients with sciatica: a systematic review.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2019</year>
            <month>Apr</month>
            <day>09</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>156</fpage>
            <pub-id pub-id-type="pmid">30967132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Subramaniapillai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Suppes</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A clinical model for identifying an inflammatory phenotype in mood disorders.</article-title>
            <source>J Psychiatr Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>113</volume>
            <fpage>148</fpage>
            <page-range>148-158</page-range>
            <pub-id pub-id-type="pmid">30954775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanderschueren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deeren</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Knockaert</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bobbaers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bossuyt</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Peetermans</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Extremely elevated C-reactive protein.</article-title>
            <source>Eur J Intern Med</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>430</fpage>
            <page-range>430-3</page-range>
            <pub-id pub-id-type="pmid">16962952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eschborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weitkamp</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis.</article-title>
            <source>J Perinatol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>893</fpage>
            <page-range>893-903</page-range>
            <pub-id pub-id-type="pmid">30926891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darooghegi Mofrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milajerdi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koohdani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Surkan</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Azadbakht</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Garlic Supplementation Reduces Circulating C-reactive Protein, Tumor Necrosis Factor, and Interleukin-6 in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</article-title>
            <source>J Nutr</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>149</volume>
            <issue>4</issue>
            <fpage>605</fpage>
            <page-range>605-618</page-range>
            <pub-id pub-id-type="pmid">30949665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dick</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Magill</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>TCH</given-names>
              </name>
              <name>
                <surname>Kokkinakis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Norman-Taylor</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>C-reactive protein: what to expect after bony hip surgery for nonambulatory children and adolescents with cerebral palsy.</article-title>
            <source>J Pediatr Orthop B</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-313</page-range>
            <pub-id pub-id-type="pmid">30925527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McKechnie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doumouras</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Handler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eskicioglu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gmora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anvari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Value of C-Reactive Protein Levels in Postoperative Infectious Complications After Bariatric Surgery: a Systematic Review and Meta-Analysis.</article-title>
            <source>Obes Surg</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>2022</fpage>
            <page-range>2022-2029</page-range>
            <pub-id pub-id-type="pmid">30895509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johns</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moschonas</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ossei-Gerning</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kassianos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Halcox</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study.</article-title>
            <source>Open Heart</source>
            <year>2018</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e000849</fpage>
            <pub-id pub-id-type="pmid">30564373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhardwaj</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anvikar</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Pande</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>C-reactive protein as a prognostic marker of <italic>Plasmodiumfalciparum</italic> malaria severity.</article-title>
            <source>J Vector Borne Dis</source>
            <year>2019</year>
            <season>Apr-Jun</season>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-126</page-range>
            <pub-id pub-id-type="pmid">31397387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vuong</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Le Duyen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>DTH</given-names>
              </name>
              <name>
                <surname>Vinh Chau</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Van Kinh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chanpheaktra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lum</surname>
                <given-names>LCS</given-names>
              </name>
              <name>
                <surname>Pleit&#x000e9;s</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Rosenberger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jaenisch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Halleux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olliaro</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Wills</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yacoub</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study.</article-title>
            <source>BMC Med</source>
            <year>2020</year>
            <month>Feb</month>
            <day>17</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">32063229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18744.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Souza Pires-Neto</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>da Silva Gra&#x000e7;a Amoras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Queiroz</surname>
                <given-names>MAF</given-names>
              </name>
              <name>
                <surname>Demachki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>da Silva Conde</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ishak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cayres-Vallinoto</surname>
                <given-names>IMV</given-names>
              </name>
              <name>
                <surname>Vallinoto</surname>
                <given-names>ACR</given-names>
              </name>
            </person-group>
            <article-title>Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C.</article-title>
            <source>Infect Genet Evol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>80</volume>
            <fpage>104200</fpage>
            <pub-id pub-id-type="pmid">31962161</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
